Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven R Feldman

Showing results (151-160 of 1,291) with videos related to

Pageof 130
Sort By:
Dermatologic Therapy|September 24, 2004
The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?Stephen R Rapp, Steven R Feldman
American Journal of Clinical Dermatology|October 15, 2009
Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulationsSteven R Feldman, Brad A Yentzer
Archives of Dermatological Research|April 30, 2024
Self-reported adherence logs in dermatology: convenient metric or complicating data collection?Max E Oscherwitz, Steven R Feldman
Journal of Cutaneous Medicine and Surgery|March 17, 2015
Reasons for Treatment Changes in Patients With Moderate to Severe PsoriasisKathryn L Anderson, Steven R Feldman
Dermatology Online Journal|July 2, 2020
Analyzing China's contributions to major dermatologic journals from the past 20 yearsJeremy K Bray, Steven R Feldman
International Journal of Dermatology|February 28, 2024
Patient satisfaction surveys: who benefits?Shirley P Parraga, Steven R Feldman
Archives of Dermatology|November 18, 2009
Adherence, the fourth dimension in the geometry of dermatological treatmentBridgit V Nolan, Steven R Feldman
Cutis|November 23, 2016
Presenting treatment safety data: subjective interpretations of objective informationSara W Faulks, Steven R Feldman
American Journal of Clinical Dermatology|May 13, 2015
Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexateMichael E Farhangian, Steven R Feldman
Journal of the American Academy of Dermatology|August 21, 2007
Interleukin-12, interleukin-23, and psoriasis: current prospectsDorothea C Torti, Steven R Feldman
Pageof 130

Showing results (151-160 of 1,291) with videos related to

Sort By:
Pageof 130
Dermatologic Therapy|September 24, 2004
The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?Stephen R Rapp, Steven R Feldman
American Journal of Clinical Dermatology|October 15, 2009
Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulationsSteven R Feldman, Brad A Yentzer
Archives of Dermatological Research|April 30, 2024
Self-reported adherence logs in dermatology: convenient metric or complicating data collection?Max E Oscherwitz, Steven R Feldman
Journal of Cutaneous Medicine and Surgery|March 17, 2015
Reasons for Treatment Changes in Patients With Moderate to Severe PsoriasisKathryn L Anderson, Steven R Feldman
Dermatology Online Journal|July 2, 2020
Analyzing China's contributions to major dermatologic journals from the past 20 yearsJeremy K Bray, Steven R Feldman
International Journal of Dermatology|February 28, 2024
Patient satisfaction surveys: who benefits?Shirley P Parraga, Steven R Feldman
Archives of Dermatology|November 18, 2009
Adherence, the fourth dimension in the geometry of dermatological treatmentBridgit V Nolan, Steven R Feldman
Cutis|November 23, 2016
Presenting treatment safety data: subjective interpretations of objective informationSara W Faulks, Steven R Feldman
American Journal of Clinical Dermatology|May 13, 2015
Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexateMichael E Farhangian, Steven R Feldman
Journal of the American Academy of Dermatology|August 21, 2007
Interleukin-12, interleukin-23, and psoriasis: current prospectsDorothea C Torti, Steven R Feldman
Pageof 130